安科生物
(300009)
| 流通市值：102.01亿 | | | 总市值：139.66亿 |
| 流通股本：12.22亿 | | | 总股本：16.73亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 628,754,570.48 | 2,536,042,781.68 | 1,921,280,101.12 | 1,298,815,000.98 |
| 营业收入 | 628,754,570.48 | 2,536,042,781.68 | 1,921,280,101.12 | 1,298,815,000.98 |
| 二、营业总成本 | 394,534,887.63 | 1,780,935,163.99 | 1,268,341,322.03 | 842,210,918.23 |
| 营业成本 | 144,887,005.33 | 573,308,673.39 | 427,566,812.85 | 282,541,657.51 |
| 税金及附加 | 5,498,189.7 | 21,351,075.98 | 16,291,120.14 | 11,332,785.56 |
| 销售费用 | 171,303,320.18 | 819,380,286.48 | 569,872,415.82 | 381,236,082.38 |
| 管理费用 | 36,515,762.1 | 167,248,514.77 | 127,501,408.32 | 86,836,985.52 |
| 研发费用 | 33,910,492.09 | 201,286,759.72 | 128,568,208.02 | 81,389,550.12 |
| 财务费用 | 2,420,118.23 | -1,640,146.35 | -1,458,643.12 | -1,126,142.86 |
| 其中:利息费用 | 570,651.19 | 2,404,671.12 | 2,086,517.92 | 1,442,672.3 |
| 其中:利息收入 | 919,845.28 | 4,985,499.52 | 4,234,648.56 | 2,892,453.53 |
| 加:公允价值变动收益 | -979,808.74 | 10,518,654.06 | -2,566,129.73 | 1,210,799.94 |
| 加:投资收益 | 6,347,951.75 | 15,434,956.87 | 14,703,993.65 | 7,254,879.77 |
| 资产处置收益 | 229,899.18 | 1,089,285.1 | 925,226.73 | 1,090,558.93 |
| 资产减值损失(新) | 0 | -7,850,983.9 | -359,410.89 | -359,410.89 |
| 信用减值损失(新) | -3,321,652.67 | -8,964,284.53 | 4,557,420.96 | 2,712,977.56 |
| 其他收益 | 11,470,548.23 | 41,061,568.17 | 29,164,487.19 | 24,482,956.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 247,966,620.6 | 806,396,813.46 | 699,364,367 | 492,996,844.14 |
| 加:营业外收入 | -26,694.69 | 1,003,079.59 | 712,568.27 | 562,792.3 |
| 减:营业外支出 | 77,019.65 | 4,383,190.13 | 1,801,598.81 | 1,541,555 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 247,862,906.26 | 803,016,702.92 | 698,275,336.46 | 492,018,081.44 |
| 减:所得税费用 | 34,547,937.89 | 87,178,796.76 | 98,360,204.89 | 68,247,433.27 |
| 六、净利润 | 213,314,968.37 | 715,837,906.16 | 599,915,131.57 | 423,770,648.17 |
| 持续经营净利润 | 213,314,968.37 | 715,837,906.16 | 599,915,131.57 | 423,770,648.17 |
| 归属于母公司股东的净利润 | 209,002,473.85 | 706,948,363.86 | 589,719,954.61 | 416,132,684.8 |
| 少数股东损益 | 4,312,494.52 | 8,889,542.3 | 10,195,176.96 | 7,637,963.37 |
| (一)基本每股收益 | 0.12 | 0.42 | 0.35 | 0.25 |
| (二)稀释每股收益 | 0.12 | 0.42 | 0.35 | 0.25 |
| 八、其他综合收益 | -44,881,085.5 | - | - | - |
| 归属于母公司股东的其他综合收益 | -44,881,085.5 | - | - | - |
| 九、综合收益总额 | 168,433,882.87 | 715,837,906.16 | 599,915,131.57 | 423,770,648.17 |
| 归属于母公司股东的综合收益总额 | 164,121,388.35 | 706,948,363.86 | 589,719,954.61 | 416,132,684.8 |
| 归属于少数股东的综合收益总额 | 4,312,494.52 | 8,889,542.3 | 10,195,176.96 | 7,637,963.37 |
| 公告日期 | 2025-04-29 | 2025-03-28 | 2024-10-25 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |